Literature DB >> 29478109

Prediction efficiency of serum cystatin C for clinical outcome in patients with cardiac resynchronization therapy.

Zhong-Bao Ruan1, Ge-Cai Chen2, Yin Ren2, Li Zhu2.   

Abstract

BACKGROUND: Since only 60-70% of select patients with chronic heart failure (CHF) are responders in cardiac resynchronization therapy (CRT), this study aimed to investigate whether serum cystatin C (Cys C) can be used to evaluate the effectiveness of CRT in patients with CHF.
METHODS: Seventy-six patients implanted with CRT were retrospectively enrolled. The concentration of serum Cys C was detected and echocardiography was performed before and after 15 days, 1 month, and 6 months of CRT.
RESULTS: There were 52 patients (68.4%) who responded to CRT during the follow-up. In the responding group, compared with the pre-CRT, the cardiac function, QRS interval, left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), and left ventricular ejection fraction (LVEF) were significantly improved at 6 months after implantation (P < 0.05), but the level of serum Cys C decreased significantly from 1 month after CRT. There was no change of all the parameters in the non-responding group during the follow-up. In the responding group, the ΔCys C% is significantly related to the ΔLVEDV%, ΔLVESV%, and ΔLVEF%. Multivariate linear analysis shows that the ΔCys C% is significantly related to the ΔLVEDV%. The level of serum Cys C before CRT implantation could predict the response to CRT (AUC = 0.78, P < 0.05). Univariate analysis and multivariate analysis demonstrated that the level of Cys C remained independent predictor for CRT (P = 0.028, 95% CI 0.919-1.348).
CONCLUSIONS: The level of serum Cys C before CRT implantation is valuable in predicting the response to CRT.

Entities:  

Keywords:  Cardiac resynchronization therapy; Chronic heart failure; Cystatin C

Mesh:

Substances:

Year:  2018        PMID: 29478109     DOI: 10.1007/s11845-018-1771-8

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  11 in total

1.  Can the difference in serum concentration of urea and cystatin C be used in diagnosis and prognosis of heart failure?

Authors:  Ante Matana; Teodora Zaninović Jurjević; Zrinka Matana Kaštelan
Journal:  Med Hypotheses       Date:  2014-07-18       Impact factor: 1.538

2.  NT-proBNP: The Gold Standard Biomarker in Heart Failure.

Authors:  Paul M McKie; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2016-12-06       Impact factor: 24.094

Review 3.  Novel biomarkers and therapies in cardiorenal syndrome.

Authors:  Roberto Latini; Aneta Aleksova; Serge Masson
Journal:  Curr Opin Pharmacol       Date:  2016-02-16       Impact factor: 5.547

4.  Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With Cardiac Resynchronization: Results From the REVERSE Trial.

Authors:  Martin St John Sutton; Cecilia Linde; Michael R Gold; William T Abraham; Stefano Ghio; Jeffrey Cerkvenik; Jean-Claude Daubert
Journal:  JACC Heart Fail       Date:  2017-03       Impact factor: 12.035

Review 5.  Cardiac resynchronization therapy: results, challenges and perspectives for the future.

Authors:  Marcus Ståhlberg; Frieder Braunschweig; Fredrik Gadler; Lars Mortensen; Lars H Lund; Cecilia Linde
Journal:  Scand Cardiovasc J       Date:  2016-08-30       Impact factor: 1.589

6.  The potential of cystatin-C to evaluate the prognosis of acute heart failure: A comparative study.

Authors:  Tae-Hun Kim; Hyungseop Kim; In-Cheol Kim
Journal:  Acute Card Care       Date:  2016-08-05

7.  Mechanical abnormalities detected with conventional echocardiography are associated with response and midterm survival in CRT.

Authors:  Adelina Doltra; Bart Bijnens; José M Tolosana; Roger Borràs; Malek Khatib; Diego Penela; Teresa Maria De Caralt; María Ángeles Castel; Antonio Berruezo; Josep Brugada; Lluís Mont; Marta Sitges
Journal:  JACC Cardiovasc Imaging       Date:  2014-09-17

Review 8.  Cardiac resynchronization therapy in patients with mild heart failure is a reversal therapy.

Authors:  Sadeq Ali-Hassan-Al-Saegh; Seyed Jalil Mirhosseini; Ali Akbar Karimi-Bondarabadi; Azadeh Sahidzadeh; Parisa Mahdavi; Mahbube Tahernejad; Safieyehsadat Heydari; Alexander Weymann; Mohamed Zeriouh; Anton Sabashnikov; Aron-Frederik Popov
Journal:  Indian Heart J       Date:  2016-08-25

Review 9.  Renal Denervation for Chronic Heart Failure: Background and Pathophysiological Rationale.

Authors:  Michael Böhm; Sebastian Ewen; Felix Mahfoud
Journal:  Korean Circ J       Date:  2016-12-02       Impact factor: 3.243

10.  Cystatin C, N-terminal probrain natriuretic peptides and outcomes in acute heart failure with acute kidney injury in a 12-month follow-up: Insights into the cardiorenal syndrome.

Authors:  Zhong-Bao Ruan; Li Zhu; Yi-Gang Yin; Ge-Cai Chen
Journal:  J Res Med Sci       Date:  2014-05       Impact factor: 1.852

View more
  1 in total

1.  Association of QRS narrowing with response to cardiac resynchronization therapy-a systematic review and meta-analysis of observational studies.

Authors:  George Bazoukis; Katerina K Naka; Alawi Alsheikh-Ali; Gary Tse; Konstantinos P Letsas; Panagiotis Korantzopoulos; Tong Liu; Cynthia Yeung; Michael Efremidis; Konstantinos Tsioufis; Adrian Baranchuk; Stavros Stavrakis
Journal:  Heart Fail Rev       Date:  2020-09       Impact factor: 4.214

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.